|
steve usdin
@
steveusdin1
|
|
Washington Editor, BioCentury. Author: Bureau of Spies & Engineering Communism.
|
|
|
2.607
Tweetovi
|
261
Pratim
|
1.817
Osobe koje vas prate
|
| Tweetovi |
|
steve usdin
@steveusdin1
|
12 h |
|
Today: WHO says Gilead’s remdesivir most promising drug for #2019-nCoV. WHO plans master protocol to test multiple therapies. FDA authorizes emergency use Dx. HHS funds Regeneron coronavirus antibody. And more at biocentury.com/coronavirus. No paywall.
|
||
|
|
||
| steve usdin proslijedio/la je tweet | ||
|
Jeffrey Cranmer
@jeff_cranmer
|
15 h |
|
.@WHO draft report: $GILD's remdesivir most "promising" candidate to treat #2019nCoV, planning for trial under way. $GILD says its “investing pretty heavily” in manufacturing of the therapy “to make sure we’re prepared as best as we can” via @BioCentury biocentury.com/article/304374
|
||
|
|
||
|
steve usdin
@steveusdin1
|
15 h |
|
WHO expert group says Gilead's remdesivir most promising to treat #2019-nCoV, then protease inhibitors. MERS antibodies not likely to work. biocentury.com/article/304374
|
||
|
|
||
|
steve usdin
@steveusdin1
|
15 h |
|
WHO prioritizing Gilead's remdesivir, designing master protocol to test multiple drug for 2019-nCoV outbreak biocentury.com/article/304374
|
||
|
|
||
| steve usdin proslijedio/la je tweet | ||
|
Derek Lowe
@Dereklowe
|
4. velj |
|
(1/2) I wanted to highlight two sources of coronavirus news which some respected biopharma news sources have placed in front of their usual paywalls. Here's Biocentury's coverage:
biocentury.com/coronavirus
|
||
|
|
||
| steve usdin proslijedio/la je tweet | ||
|
Josh Berlin
@BioPharmaJosh
|
4. velj |
|
We have created a free webpage that collects @BioCentury analysis of the #coronavirus outbreak. Please bookmark this page. It will be updated frequently. The most recent story tracks clinical trials. biocentury.com/coronavirus #2019nCoV pic.twitter.com/hCSzCPQit2
|
||
|
|
||
|
steve usdin
@steveusdin1
|
4. velj |
|
Gilead preparing a trial in China of remdesivir to treat 2019-nCoV: biocentury.com/article/304364.
At least 9 trials of #2019-nCoV therapies are underway. biocentury.com/article/304364
All BioCentury coverage of the outbreak is in front of the paywall at biocentury.com/coronavirus.
@V2019N pic.twitter.com/eKrq2JK5Sq
|
||
|
|
||
|
steve usdin
@steveusdin1
|
4. velj |
|
Data will be critical to curtailing the #2019-nCoV outbreak. It looks like China is starting trials to gather data about treatments: biocentury.com/article/304364. List of 9 trials below. Also Gilead preparing a trial in China of remdesivir to treat 2019-nCoV: biocentury.com/article/304364. pic.twitter.com/uOCDalHRmA
|
||
|
|
||
|
steve usdin
@steveusdin1
|
4. velj |
|
Gilead preparing a trial in China of remdesivir to treat 2019-nCoV: biocentury.com/article/304364.
Meanwhile, at least 9 trials of #2019-nCoV therapies are underway. biocentury.com/article/304364
All BioCentury coverage of the outbreak is in front of the paywall at biocentury.com/coronavirus. pic.twitter.com/MR9Bhpq0Pn
|
||
|
|
||
|
steve usdin
@steveusdin1
|
3. velj |
|
FDA, FTC vow to crack down on advertising and commercial practices that impede biosimilar uptake biocentury.com/article/304360
|
||
|
|
||
|
steve usdin
@steveusdin1
|
3. velj |
|
This will stretch supplies of vaccines, which could be important in a pandemic. Also could make vaccines more effective if #2019-nCoV "drifts." twitter.com/jeff_cranmer/s…
|
||
|
|
||
|
steve usdin
@steveusdin1
|
3. velj |
|
An elegant explanation of an important study by the founder of Immuno-oncology - Steve Rosenberg. He has found a way to make T cell therapies by taking T cells from blood rather than from tumors, which is far less invasive. biocentury.com/article/304348…
|
||
|
|
||
|
steve usdin
@steveusdin1
|
3. velj |
|
GlaxoSmithKline to make its immune-boosting adjuvant technology available to #2019-nCoV vaccine makers. This will dramatically stretch supplies and could make vaccines more effective. The agreement covers 4 groups making vaccines funded by CEPI.
biocentury.com/article/304359
|
||
|
|
||
| steve usdin proslijedio/la je tweet | ||
|
BioCentury
@BioCentury
|
3. velj |
|
GSK to provide adjuvant to boost effectiveness and stretch supplies of #2019nCoV vaccines $GSK buff.ly/395UWSP
|
||
|
|
||
|
steve usdin
@steveusdin1
|
1. velj |
|
Another thing to consider re #2019-nCoV: China has become integrated into global drug development. China in general, and Wuhan in particular, are the sites of many drug trials. These aren't likely to priorities in a public health emergency. biocentury.com/article/304351 pic.twitter.com/W6ngfc3hZv
|
||
|
|
||
| steve usdin proslijedio/la je tweet | ||
|
Susan Schaeffer
@BiotechSusan
|
1. velj |
|
I'm excited to join this March 24 workshop on digital health as a new member of @NASEM_Health's Forum on Drug Discovery, Development, and Translation. The workshop is open to the public! Details below: twitter.com/NASEM_Health/s…
|
||
|
|
||
|
steve usdin
@steveusdin1
|
31. sij |
|
HHS declares #2019-nCoV a public health emergency. Separate declarations will be needed to allow FDA to issue Emergency Use Authorizations (EUAs), e.g., for use of unapproved diagnostics.
biocentury.com/article/304341 pic.twitter.com/J1Ue0n6l4p
|
||
|
|
||
|
steve usdin
@steveusdin1
|
31. sij |
|
These lists are of programs to develop new vaccines and therapies. I've mentioned Gilead in previous stories about efforts to repurpose existing products.
|
||
|
|
||
|
steve usdin
@steveusdin1
|
31. sij |
|
A dozen #2019-nCoV vaccine development programs have been announced, five efforts to discover and develop therapeutic antibodies. @V2019N
biocentury.com/bc-extra/clini… pic.twitter.com/GWcSDuBcZg
|
||
|
|
||
|
steve usdin
@steveusdin1
|
31. sij |
|
Biotech boards and C-suites are still overwhelmingly white and male. biocentury.com/bc-extra/polit…
|
||
|
|
||